BNP Paribas Financial Markets
AMLX icon

BNP Paribas Financial Markets’s Amylyx Pharmaceuticals AMLX Stock Holding History

BNP Paribas Financial Markets’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$298K Sell
16,577
-4,563
-22% -$70.6K ﹤0.01% 4038
2026
Q1 		$294K Sell
21,140
-4,061
-16% -$57.1K ﹤0.01% 3873
2025
Q4 		$304K Buy
25,201
+10,592
+73% +$144K ﹤0.01% 3847
2025
Q3 		$199K Buy
14,609
+7,342
+101% +$69.1K ﹤0.01% 4016
2025
Q2 		$46.6K Buy
7,267
+5,904
+433% +$28.7K ﹤0.01% 4285
2025
Q1 		$4.83K Buy
1,363
+214
+19% +$762 ﹤0.01% 4859
2024
Q4 		$4.34K Buy
+1,149
New +$5.41K ﹤0.01% 4945

Other funds holding AMLX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BNP Paribas Financial Markets's AMLX Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its Amylyx Pharmaceuticals (AMLX) stake by 22% in Q2 2026, selling an estimated $70.6K and leaving 16,577 shares worth $298K. The position accounts for ﹤0.01% of the portfolio, ranked #4038.

BNP Paribas Financial Markets first reported a position in AMLX in Q4 2024 and has held it in 7 quarters since. The position peaked at $304K in Q4 2025. 182 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • BNP Paribas Financial Markets held 16,577 shares of Amylyx Pharmaceuticals worth $298K as of Q2 2026.
  • BNP Paribas Financial Markets sold 4,563 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $70.6K.
  • Amylyx Pharmaceuticals made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #4038 holding.
  • BNP Paribas Financial Markets first reported a position in Amylyx Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • BNP Paribas Financial Markets's Amylyx Pharmaceuticals position peaked at $304K in Q4 2025.
  • 182 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.